Trial Profile
Descriptive Pharmacoepidemiological Study on the Use of Symbicort Turbuhaler in the Treatment of Asthma in France and Impact of a New Therapeutic Strategy on the Compliance and Control of Asthma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Dec 2011
Price :
$35
*
At a glance
- Drugs Budesonide/formoterol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms SYMBIOSE
- Sponsors AstraZeneca
- 28 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Feb 2011 Planned end date changed from Jul 2011 to Aug 2011 as reported by ClinicalTrials.gov.
- 26 Mar 2010 Planned number of patients changed from 800 to 382 as reported by ClinicalTrials.gov.